Eckert & Ziegler BEBIG´s HDR afterloading system MultiSource® has been approved for sale in China

Seneffe, Belgium, February 27, 2012. Eckert & Ziegler BEBIG announced today that
the Chinese State Food and Drug Administration (SFDA) has approved its
MultiSource® HDR afterloading system for brachytherapy.

MultiSource® is a state-of-the-art afterloader designed for the entire range of
HDR brachytherapy applications for cancer treatment. Even complex implants can
be performed easily. The system provides highest quality and optimal treatment
safety, based on Eckert & Ziegler´s 35 years of experience in accordance with
German manufacturing standards.

HDR brachytherapy is a form of radiotherapy in which cancer is treated by
irradiation from a short distance. The radioactive source is placed directly
inside or close to the tumor´s site. This reduces the risk of damaging the
surrounding healthy tissue, while providing a very high dose of localized
radiation to the tumor cells.

With MultiSource®, the customer has the possibility to choose either a well-
proven Ir-192 source or a particularly cost-effective Co-60 source with a half
life time of 5,26 years. Both sources have two things in common: a small size
and a favourable dose distribution. The Co-60 source is still unique worldwide
and represents the latest high end technology for miniaturized sources on the
medical device market. Eckert & Ziegler BEBIG has installed more than 180
MultiSource® devices all over the world, in most cases equipped with a Co-60
source.

Eckert & Ziegler BEBIG exclusively integrates an In-Vivo Dosimetry System inside
MultiSource®, as the customer requires. This saves space and makes handling more
comfortable. A complete range of applicators, catheters, needles and templates
allows to perform not only gynaecological, but also esophagus, bronchus, skin
and prostate cancer treatments. An innovative and user friendly treatment
planning system, HDRplus(TM) completes the HDR afterloading setup.

Abel Luzuriaga, Managing Director of Eckert & Ziegler BEBIG said: "We are happy
to see the positive developments in the Chinese health care system and have been
awaiting the SFDA approval with great expectations. The registration of
MultiSource® in China is a significant opportunity for us to contribute in
future to the patient-centred care in China and to expand our activities to this
very important market with our well proven brachytherapy solutions. Compared to
Europe, China has high incidences of esophagus and nasopharynx cancer, which
both can be treated with brachytherapy.

" The MultiSource® system will be presented to the Chinese brachytherapy
community during the ESTRO Teaching Course "Image-Guided Radiotherapy &
Chemotherapy in Gynaecological Cancer - focus on Adaptive Brachytherapy" that
will take place in Beijing in March 4-8, 2012.
Participants will have the opportunity to ask questions about the MultiSource®
system and to receive detailed explanations from the Eckert & Ziegler BEBIG
experts.

About Eckert & Ziegler BEBIG

Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry.

Its core business is the treatment of cancer using brachytherapy, a special form
of radiation therapy.

Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in Germany and
subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
has a worldwide network of distributors and agents to support the international
marketing of its product line.

The company´s products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.

Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters:
EZBG.BR; Bloomberg: EZBG:BB).

Contact: Claudia Mihlan
Head of Marketing Paul-Emmanuel Goethals
Karolin Riehle
Investor Relations
Tel.: [phone]
E-Mail:[e-mail]
Website:www.bebig.eu

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE

[HUG#1589356]

Wertpapiere des Artikels:
BE0003689032